1. A functional SNP in the promoter region of TCOF1 is associated with reduced gene expression and YY1 DNA-protein interaction.
- Author
-
Masotti C, Armelin-Correa LM, Splendore A, Lin CJ, Barbosa A, Sogayar MC, and Passos-Bueno MR
- Subjects
- Alleles, Animals, Base Sequence, Binding, Competitive, Brazil, Cell Line, Tumor, DNA Mutational Analysis, Dogs, Electrophoretic Mobility Shift Assay, Family Health, Female, Gene Expression Regulation, Gene Frequency, Genetic Testing, Genetic Vectors genetics, Humans, Male, Mandibulofacial Dysostosis diagnosis, Mandibulofacial Dysostosis genetics, Mice, Molecular Sequence Data, Mutation, Nuclear Proteins metabolism, Pan troglodytes, Pedigree, Phosphoproteins metabolism, Protein Binding genetics, Rats, Sequence Alignment, Sequence Homology, Nucleic Acid, Species Specificity, Transfection, YY1 Transcription Factor genetics, Nuclear Proteins genetics, Phosphoproteins genetics, Polymorphism, Single Nucleotide, Promoter Regions, Genetic genetics, YY1 Transcription Factor metabolism
- Abstract
Treacher Collins syndrome (TCS) is an autosomal dominant craniofacial malformation caused by null mutations in the TCOF1 gene. High inter and intra familial clinical variability, ranging from mild malar hypoplasia to perinatal death due to airway collapse is observed, but, to date, no genotype-phenotype correlation has been reported. Considering haploinsufficiency as the molecular mechanism underlying the disease, we have hypothesized that mutations in the promoter region of the gene, which has never been previously characterized, in trans with a pathogenic mutation, could modulate the phenotype. Therefore, the aims of the present study were to determine the TCOF1 gene's core promoter and to identify mutations in this region that could contribute to the phenotypic variation observed in this syndrome. We have delimitated the minimal promoter to a region of less than 150 bp, with 63% of identity among 5 different species. We screened 1.2 kbp of the TCOF1 5' flanking sequence in the DNA obtained from 21 patients and 51 controls and identified four new single nucleotide polymorphisms (SNPs), one of which (-346C>T), was proved to be functional, as it decreased the promoter activity by 38%. Electrophoretic mobility shift assay (EMSA) analysis demonstrated that the -346T allele impairs DNA-binding to the YY1 transcription factor. This promoter variant represents a candidate allele to explain the clinical variability in patients bearing TCS.
- Published
- 2005
- Full Text
- View/download PDF